Financial research concept

Clinical Trial Phase: Phase 1, Phase 2, and Phase 3 in Drug Development

Clinical trial phase describes where a drug-development program sits from initial human testing through confirmatory efficacy and safety studies.

By Lee BaileyPublished Sep 21, 2026
Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date
Sep 21, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context
16 connected conceptsPart of the reviewed Biopharma Development and Commercialization; issuer definitions remain distinct where disclosed.
Company examples
1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
  1. Phase 1, 2, and 3
  2. Investor use
  3. Part of the Biopharma Development and Commercialization
  4. See It in Company Research
  5. Continue Research

Clinical trial phase describes the stage of human testing for an investigational drug or biologic.

Phase 1, 2, and 3

FDA describes Phase 1 as the initial introduction into humans, with emphasis on pharmacology, safety, and dose-related effects. Phase 2 provides preliminary evidence of effectiveness in patients while continuing safety evaluation. Phase 3 expands testing to gather the evidence needed to evaluate overall benefit-risk and support labeling.

Phases may overlap, and a development program is not guaranteed to move sequentially from one phase to the next.

Investor use

Trial phase helps investors frame:

  • remaining development risk;
  • expected evidence maturity;
  • likely capital needs;
  • time to a potential marketing application; and
  • which upcoming events can materially change the program's value.

A Phase 3 asset is later stage than a Phase 1 asset, but phase number alone does not measure probability of approval.

Immuneering, for example, described varegacestat as having positive topline Phase 3 results while other pipeline assets remained in Phase 1.

Sources:

Clinical trial phase is a development-stage classification, not an approval probability.

Part of the Biopharma Development and Commercialization

Connect clinical-trial evidence, FDA application and expedited pathways, collaboration economics, gross-to-net commercialization, and loss-of-exclusivity risk to understand drug-development businesses.

How the model fits together
  • Clinical evidence and execution: Trial phase frames development maturity, enrollment affects execution timing, primary and secondary endpoints define the prespecified evidence hierarchy, and a readout converts that study design into new evidence for investors to interpret.
  • FDA pathway and review milestones: NDA and BLA submissions begin formal marketing review for drugs and biologics, PDUFA dates frame target action timing, and accelerated approval, Breakthrough Therapy, and Orphan Drug designations describe distinct regulatory pathways or incentives rather than approval outcomes.
  • Commercialization, partnerships, and exclusivity: Gross-to-net adjustments bridge gross product demand to recognized revenue, royalties and milestones describe partner economics, and patent expiry plus loss of exclusivity frame when legal protection may translate into competitive revenue erosion.

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare biopharma stocks

Continue into stock comparison for pipeline stage, regulatory milestones, commercialization economics, concentration, and valuation context.

Continue research

Explore more topics in the Financial Research Encyclopedia.